Abstract is: Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. It is given after the wound is cleaned with soap and water or povidone-iodine and is followed by a course of rabies vaccine. It is given by injection into the site of the wound and into a muscle. It is not needed in people who have been previously vaccinated against rabies. Common side effects include pain at the site of injection, fever, and headache. Severe allergic reactions such as anaphylaxis may rarely occur. Use during pregnancy is not known to harm the baby. It works by binding to the rabies virus before it can enter nerve tissue. After the virus has entered the central nervous system, rabies immunoglobulin is no longer useful. The use of rabies immunoglobulin in the form of blood serum dates from 1891. Use became common within medicine in the 1950s. It is on the World Health Organization's List of Essential Medicines. Rabies immunoglobulin is expensive and hard to come by in the developing world. In the United States it is estimated to be more than US$1,000.00 per dose. It is made from the blood plasma of people or horses who have high levels of the antibody in their blood. The horse version is less expensive but has a higher rate of side effects.
| P267 | ATC code | J06AA06 |
| J06BB05 | ||
| P9635 | electronic Essential Medicines List medicine ID | 462 |
| P2671 | Google Knowledge Graph ID | /g/11c2q5gh5s |
| P6366 | Microsoft Academic ID | 2780494762 |
| P11143 | WikiProjectMed ID | Rabies immunoglobulin |
| P2175 | medical condition treated | rabies | Q39222 |
| P3489 | pregnancy category | US pregnancy category C | Q28123617 |
| Q96579670 | A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG) |
| Q100431862 | A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG) |
| Q93633766 | A collaborative study to establish an International Standard Rabies immunoglobulin of human origin |
| Q99714760 | Abandon of intramuscular administration of rabies immunoglobulin for post-exposure prophylaxis in the revised guidelines in the Netherlands in 2018: cost and volume savings |
| Q56576872 | Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin |
| Q47616794 | Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study |
| Q72593752 | Confirmation of need for rabies immunoglobulin as well as post-exposure vaccine |
| Q39730585 | Equine rabies immunoglobulin: a study on its clinical safety. |
| Q46778540 | Evaluation of a new premedication protocol for administration of equine rabies immunoglobulin in patients with hypersensitivity |
| Q77429475 | Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine |
| Q37530343 | Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of In vitro and In vivo studies |
| Q68162415 | Human rabies immunoglobulin assayed by the rapid fluorescent focus inhibition test suppresses active rabies immunization |
| Q47571006 | Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination |
| Q49502107 | Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children |
| Q40300404 | Injecting rabies immunoglobulin (RIG) into wounds only: A significant saving of lives and costly RIG. |
| Q68515861 | Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment |
| Q69487588 | Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects |
| Q36560046 | Is injecting a finger with rabies immunoglobulin dangerous? |
| Q45740467 | Issues of human rabies immunoglobulin and vaccine: policy versus practice |
| Q72146050 | Methods for the purification of equine rabies immunoglobulin: effects on yield and biological activity |
| Q97561459 | RABIES IMMUNOGLOBULIN: BRIEF HISTORY AND RECENT EXPERIENCES IN CÔTE D'IVOIRE |
| Q41588040 | Rabies Vaccine and Rabies Immunoglobulin in Cambodia: Use and Obstacles to Use. |
| Q33338456 | Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab). |
| Q39374912 | Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines |
| Q40340145 | Role of systemic injection of rabies immunoglobulin in rabies vaccination |
| Q64233525 | Serum Sickness after Equine Rabies Immunoglobulin in Identical Male Twins: Two Case Reports |
| Q50730214 | Sex- and age-related differences in rabies immunoglobulin hypersensitivity. |
| Q64129499 | The comparison of the WHO standard rabies immunoglobulin and the national standard human rabies immunoglobulin used in the rapid fluorescent focus inhibition test (RFFIT) |
| Q86725837 | The importance of rabies immunoglobulin in postexposure prophylaxis |
| Q73240336 | Therapeutic failures with rabies vaccine and rabies immunoglobulin |
| Q84087361 | There is a need for regularly updated information on rabies immunoglobulin availability in rabies endemic countries |
| Q38997495 | Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')2 fragments |
| Q91603115 | Using a modified rabies immunoglobulin protocol in a crisis of unavailability: Ethical and practical challenges |
| Q92506596 | Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by "pooling strategy" |
| Q74338396 | [10 years' of production and use of human rabies immunoglobulin in Yugoslavia] |
| Q90026116 | [Advances in Application of Rabies Immunoglobulin] |
| Q37155 | World Health Organization Model List of Essential Medicines | has part(s) | P527 |
| Arabic (ar / Q13955) | غلوبيولين مناعي لداء الكلب | wikipedia |
| Rabies immunoglobulin | wikipedia | |
| Inmunoglobulina contra la rabia | wikipedia | |
| Immunoglobuline antirabique | wikipedia | |
| Imunoglobulin rabies | wikipedia | |
| or | ରାବିଜ ଇମ୍ମ୍ୟୁନୋଗ୍ଲୋବ୍ୟୁଲିନ | wikipedia |
| Антирабический иммуноглобулин | wikipedia | |
| Хумани антирабијски имуноглобулин | wikipedia |
Search more.